"Leukopenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Descriptor ID |
D007970
|
| MeSH Number(s) |
C15.378.553.546
|
| Concept/Terms |
Leukopenia- Leukopenia
- Leukopenias
- Leukocytopenia
- Leukocytopenias
|
Below are MeSH descriptors whose meaning is more general than "Leukopenia".
Below are MeSH descriptors whose meaning is more specific than "Leukopenia".
This graph shows the total number of publications written about "Leukopenia" by people in this website by year, and whether "Leukopenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukopenia" by people in Profiles.
-
Murray JE, Bicknell LS, Yigit G, Duker AL, van Kogelenberg M, Haghayegh S, Wieczorek D, Kayserili H, Albert MH, Wise CA, Brandon J, Kleefstra T, Warris A, van der Flier M, Bamforth JS, Doonanco K, Ad?s L, Ma A, Field M, Johnson D, Shackley F, Firth H, Woods CG, N?rnberg P, Gatti RA, Hurles M, Bober MB, Wollnik B, Jackson AP. Extreme growth failure is a common presentation of ligase IV deficiency. Hum Mutat. 2014 Jan; 35(1):76-85.
-
Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013 Apr 10; 31(11):1405-14.
-
Dallal RM, Leighton J, Trang A. Analysis of leukopenia and anemia after gastric bypass surgery. Surg Obes Relat Dis. 2012 Mar-Apr; 8(2):164-8.
-
Valicenti RK, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study. Int J Radiat Oncol Biol Phys. 2011 Mar 1; 79(3):732-7.
-
Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Greven K. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys. 2007 Jan 1; 67(1):104-9.
-
Asadi-Pooya AA, Ghetmiri E. Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. Epilepsy Behav. 2006 Feb; 8(1):228-31.
-
Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995 Jan 01; 75(1):11-7.
-
Petrelli NJ, Rustum YM, Bruckner H, Stablein D. The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma. Adv Exp Med Biol. 1988; 244:143-55.
-
Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984 Nov 29; 311(22):1407-13.